Anticoagulant Citrate Dextrose A Solution
FDA Label NDC 23731-6051

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Citra Labs Llc for the product Anticoagulant Citrate Dextrose A (NDC 23731-6051). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding description, clinical pharmacology, indications and usage, contraindications, warnings, general, information for patients, carcinogenesis, mutagenesis, impairment of fertility, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Clinical Pharmacology

ACD-A acts as an anticoagulant by the action of the citrate ion chelating free ionized calcium, thus making calcium unavailable to the coagulation system.

Indications And Usage

Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P. (ACD-A), is intended for use as an anticoagulant in the extracorporeal blood processing with Autologous PRP Systems in production of platelet rich plasma (PRP). Refer to the manufacturer's Operator's Manual of the Autologous PRP System for the Directions for Use.

Contraindications

NOT FOR DIRECT INTRAVENOUS INFUSION

Warnings

NOT FOR DIRECT INTRAVENOUS INFUSION

General

  • Aseptic technique must be maintained at all times.
  • ACD-A solution is a clear and colorless solution. If the product shows any cloudiness or turbidity, the product should be discarded.
  • The closure system provides a biological barrier and should be intact – discard product if system is compromised.

Information For Patients

None.

Carcinogenesis, Mutagenesis, Impairment Of Fertility

Long-term studies in animals have not been performed to evaluate the carcinogenic potential of ACD-A.

Pregnancy

Long-term studies in animals have not been performed to evaluate the effects of ACD- A on pregnant women.

Pediatric Use

The safety and effectiveness of ACD-A in children have not been established.

Adverse Reactions

Not applicable. This product is used as an anticoagulant in the extracorporeal blood processing with Autologous PRP Systems in production of platelet rich plasma (PRP).

Overdosage

Not applicable. This product is used as an anticoagulant in the extracorporeal blood processing with Autologous PRP systems in production of platelet rich plasma (PRP).

Dosage And Administration

Refer to the manufacturer's Operator's Manual of the Autologous PRP System for the Directions for Use.

Rx Only

Caution: Federal Law (US) restricts this devise to sale by or on the order of a Physician.

How Supplied

Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P., (ACD-A)

 REFSIZECASE
 PN 9350-1030 mL10 Vials/Case
 PN 9350-2530 mL25 Vials/Case

Storage And Handling

It is recommended that the product be stored at ambient room temperature, 24 °C (75 °F); however, the product can be stored between 15 °C (59 °F) and 30 °C (86 °F). Protect from freezing and exposure to excessive heat should be minimized.

Other

Manufactured & Distributed by:
CitraLabs™
55 Messina Drive, Braintree, MA 02184
Phone Number: 1-800-299-3411

Authorized Representative:
Biomet U.K. Ltd.
Waterton Industrial Estate
Bridgend, South Wales, CF31 3XA
Great Britain
United Kingdom
Phone 441.65.66.55.221

Principal Display Panel (Acd A 02)

Principal Display Panel (Acd A 02)

* Please review the disclaimer below.